Aaron T. Gerds, MD, is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and serves as Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute. He is also Deputy Associate Director for Clinical Research at the Case Comprehensive Cancer Center, where he helps oversee the development, conduct, and strategic growth of cancer clinical trials across a multi-institutional enterprise.

Dr. Gerds is a nationally recognized expert in myeloproliferative neoplasms (MPNs) and other myeloid malignancies. His clinical and translational research focuses on optimizing current therapies, advancing novel targeted treatments, and redefining meaningful clinical endpoints in myelofibrosis, polycythemia vera, and related disorders. He has led and contributed to numerous multicenter clinical trials that have shaped contemporary treatment paradigms and informed national guidelines.

A committed leader in the hematology community, Dr. Gerds serves as Chair of the NCCN Guidelines Panel for Myeloproliferative Neoplasms and is the immediate past Editor-in-Chief of ASH Clinical News. He currently serves as Hematologic Oncology Associate Editor for the ASCO Educational Book. Through these roles, he works at the intersection of clinical innovation, education, and policy—helping translate emerging science into practical standards of care.

In addition to his disease-specific expertise, Dr. Gerds has a strong interest in clinical trial design, regulatory strategy, and research infrastructure, with particular emphasis on building systems that accelerate therapeutic development while maintaining rigorous scientific and ethical standards.